2026 Annual General Meeting Address to Shareholders
Released
Released
Announcement PDF
2026 Annual General Meeting
ASX Announcement
15 October 2026
2026 Annual General Meeting Address To Shareholders
Cogstate Ltd (ASX:CGS) provides the following Address to Shareholders, to be presented at today’s 2026 Annual
General Meeting.
This announcement was authorised for release by the Board of Cogstate Ltd.
For further information contact: investor@cogstate.com
About Cogstate
Cogstate Ltd (ASX: CGS) is a neuroscience technology company optimising brain health assessments to advance
the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide
rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support partners
in the delivery of electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper
assessments with real-time data capture. The company’s clinical trials solutions include quality assurance services
for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting.
For over 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical
companies and academic institutions, and the clinical care needs of physicians and patients around the world. In the
Healthcare market, Cogstate seeks to provide primary care physicians and consumers with brief, accurate and
scientifically validated digital measures of cognition, with a focus on easy to use, self-administered tests that inform
patients and save physician time. For more information, please visit www.cogstate.com.
FY26 Investor Briefing | Page 2
Important Notices
Past performance
Past performance is given for illustrative purposes only and should not be relied upon as (and is not) an indication of
Cogstate's views on its future financial performance or condition. Past performance of Cogstate cannot be relied
upon as an indicator of (and provides no guidance as to) the future performance of Cogstate. Nothing contained in
this announcement, nor any information made available to you is, or shall be relied upon as, a promise, representation,
warranty or guarantee, whether as to the past, present or future.
Future performance and forward-looking statements
This announcement contains certain “forward-looking statements”. The words “expect”, “anticipate”, “estimate”,
“intend”, “believe”, “guidance”, “should”, “could”, “may”, “will”, “predict”, “plan” and other similar expressions are
intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position
and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided
in this announcement are based on assumptions and contingencies that are subject to change without notice and
involve known and unknown risks and uncertainties and other factors that are beyond the control of Cogstate, its
directors and management. Forward-looking statements are provided as a general guide only and should not be
relied upon as an indication or guarantee of future performance.
Actual results, performance or achievements may differ materially from those expressed or implied in such
statements and any projections and assumptions on which these statements are based. These statements may
assume the success of Cogstate's business strategies, including the that the results of any of those strategies will be
realised in the period for which the forward-looking statement may have been prepared or otherwise. For example,
Cogstate's performance in any one financial period is sensitive to whether or not contracts are signed in that period,
or a subsequent period, and the rate of enrolment in trials of its customers, which are influenced by factors that are
outside of Cogstate's control.
Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or
regulations, none of Cogstate, its representatives or advisers, assumes any obligation to update these forward-
looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of
achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters
contained in this announcement. The forward-looking statements are based on information available to Cogstate as
at the date of this announcement. Except as required by law or regulation (including the ASX Listing Rules), none of
Cogstate, its representatives or advisers undertakes any obligation to provide any additional or updated information,
whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise.
Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-
looking statements.
1
© 2026 Cogstate Ltd. All rights reserved.
Annual General Meeting
15 October 2026
-----------------------------------------------------------------------------------------
Cogstate Ltd 2026 Annual General Meeting – Chairman’s Address To Shareholders
Mr. Martyn Myer A.O.
-----------------------------------------------------------------------------------------
So to begin, let me introduce our board of directors.
As I said, my name is Martyn Myer.
I’ll start by firstly introducing Richard Mohs, who joins us online today, from Chicago.
Richard is neuropsychologist by background and a former executive of Eli Lilly, who brings a
wealth of experience in Alzheimer’s disease specifically, neuroscience generally, the
conduct and clinical trials and the general running of a pharmaceutical company to the
Cogstate Board.
Joining us here in the room,
Ingrid Player, who has a background in law and brings to the Board relevant sector
experience in corporate governance, risk and sustainability. Ingrid Chairs our Audit, Risk
and Compliance Committee.
Kim Wenn, who brings more than 30 years of experience in innovation and digital
technology. Since 01 January this year, Kim has Chaired both the Nomination Committee as
2
2
Board of Directors
Martyn Myer
Non-Executive Chairman
Member: Nomination Committee
Ingrid Player
Non-Executive Director
Chair: Audit, Risk & Compliance Committee
Member: Remuneration Committee
Member: Nomination Committee
Richard Mohs
Non-Executive Director
Member: Remuneration Committee
Member: Nomination Committee
Brad O’Connor
Managing Director / CEO
Kim Wenn
Non-Executive Director
Chair: Remuneration Committee
Chair: Nomination Committee
Member: Audit, Risk & Compliance Committee
Darryl Inns
Non-Executive Director
Member: Audit, Risk & Compliance Committee
Member: Nomination Committee
well as the Remuneration Committee.
During the year, we were also pleased to welcome Darryl Inns to the Cogstate Board as an
Independent Non-Executive Director. Darryl brings more than three decades of financial,
commercial and governance experience, including deep experience in ASX-listed companies,
capital markets, investor engagement and business transformation. His insight and expertise
further strengthen the Board as Cogstate enters its next stage of development. The election
of Darryl to the Board is resolution 2 of today’s meeting.
Also present is our CEO, Brad O’Connor, who led the company since December 2005 and will
address the meeting shortly.
I would also like to welcome and introduce Kylee Byrne from Pitcher Partners, who was the
engagement partner on our external audit. Kylee will be available today to answer
shareholders’ questions relevant to the audit and accounts.
2
FY26 was a year in which Cogstate strengthened its momentum, broadened its
opportunities and reinforced the foundations required for disciplined growth. As I said at
the outset, from the Board’s perspective, this is a business that is not simply growing: it is
becoming more diversified, more scalable and more strategically embedded in the global
neuroscience and clinical-trial ecosystem.
FY26 was a landmark year for Cogstate as we delivered on our strategy of diversification
and expansion of our offering. This delivered not just record financial results, but also an
increase in the scale of the business. All the while, we were investing in technology and
planning for the next phase of growth for this business.
It is a really exciting time for everyone involved in our business, from management to Board
to shareholders, I think we all feel the sense of momentum.
3
3
3
A landmark year achieved through
diversification and expansion of offering.
Delivered record sales, revenue and profit,
while investing with discipline to support
the next phase of growth.
As we reported in August, Cogstate delivered growth in all financial metrics during the FY26
year.
The Company signed a record US$89.0 million in new net sales contracts during the year,
and entered FY27 with US$118.5 million of contracted future revenue. Of this amount, at
01 July 2026, US$48.3 million of the total contracted revenue was expected to be
recognised during FY27, providing a strong platform for the year ahead.
Revenue of US$60.9 million, Gross profit of $35.4 million, EBITDA of US$18.3 million, and
profit before tax of US$16.1 million.
Operating cashflow for FY26 of $8.5 million was not as strong as FY25, due to the fact that
we carried a high receivables balance into 30 June 2026, but we expect that to reverse in
this current December half year period. I’ll talk more about capital allocation as we go
through the presentation.
4
4
Sales Contracts
$89.0m up 116%
Contracted Revenue
Total: $118.5m
FY27: $48.3m, up 54%
Trial Starts
90 initiated (vs 35)
171 running (vs 110)
Growth
Cash $34.8M
No debt
Investment
Self-funded tech
Capital Allocation
Buyback & Dividend
Discipline
FY26 Scorecard: A Record-Breaking Year
All figures in US$ and comparison is to previous corresponding period
Revenue $60.9m
Up 15%
Gross Profit $35.4m
58% GP margin via
2H26 margin of 62%
Profitability PBT $16.1m
Up 16%
There is no doubt that those FY26 financial results that I just summarised are significant,
although the Board’s view is the greatest importance lies in what they reveal about the
quality and durability of Cogstate’s growth.
During FY26, the Company continued to reduce its historic concentration in Alzheimer’s
disease, not due to fewer opportunities but more importantly due to the expansion of our
role in other areas of CNS research. Psychiatric and mood disorders, sleep, neurological
conditions, rare disease and other indications contributed strongly to new sales, with 77%
of FY26 contract value originating outside Alzheimer’s disease. This broadening of the
portfolio increases our addressable market, reduces exposure to the development cycle of
any one therapeutic area and supports a more resilient long-term growth profile.
5
5
Trial Starts are Increasing, Portfolio is Diversifying
FY26: 90 new trial starts (vs 35 FY25)
• 14% Alzheimer’s.
• 46% Mood, Sleep & Other Neurology.
• 33% Rare Diseases.
• 7% Cancer, Metabolic and Other Diseases.
Alzheimer’s
Mood, Sleep & Other
Neurological
Rare
Cancer Metabolic &
Other
0
5
10
15
20
25
30
35
40
45
50
55
1H22 2H22 1H23 2H23 1H24 2H24 1H25 2H25 1H26 2H26
Number
of
Trials
Number of New Trial Starts, per Half Year
• Record number of new trial starts.
• Project base is broader, deeper and more resilient.
• Higher active trial numbers support multi-year
revenue opportunity.
• Increasingly positioned as the incumbent endpoint
provider as programs progress.
• Scale provides significant opportunity for
automation and further margin growth.
5
At the same time, Cogstate is expanding the depth of its contribution within each study.
The Company is evolving from a provider of digital cognitive assessments to a broader CNS
endpoint partner, combining validated technology with endpoint quality management, data
review, specialist scientific expertise and also central rating. The expansion of service areas
strengthens Cogstate’s relevance to sponsors, expands the potential value of individual trial
engagements and creates a stronger basis for repeat and follow-on work.
Today we wanted to highlight the growing importance of one such area of expansion,
central rating, and explain the growing importance of this offering for our business.
As clinical trial study design and conduct has evolved, we have evolved to meet the market.
Central Rating is an excellent example of this evolution.
Historically, assessments have been administered by clinicians working at clinical trial sites,
such as research hospitals and specialty clinics. In that setting, Cogstate's role has been to
support those site-based raters through training, certification, and ongoing quality
oversight. We ensure assessments are conducted according to protocol and monitor
performance to maintain consistency throughout the trial.
Over time, sponsors have increasingly recognized that many assessments can be delivered
more consistently by a dedicated team of highly specialized clinicians operating within a
centralized quality framework. Cogstate has developed a global network of consulting
clinicians with expertise across psychiatry, neurology, psychology, neuropsychology, and
6
6
Central Rating is
Growing Rapidly
Representing One-
Third of Contracted
Revenue
• Central Rating represents:
- 32% of total $118.5m contracted future
revenue.
- 33% of contracted $48.3m FY27 revenue.
• New Central Rating study starts increased from
3 (FY24) to 5 (FY25) to 12 (FY26).
• 28 of 171 active trials currently utilise Central
Rating.
• Margins consistent with (or better than) other
service offerings, while the clinician network
model allows costs to scale with revenue.
rare disease research.
In selected studies, a small, highly trained, and continuously calibrated subset of these
clinicians conducts assessments directly with participants via secure telehealth platforms.
We refer to this model as Central Rating.
Central Rating now represents approximately one third of Cogstate contracted revenue, even
though Central rating is only provided in 16% of clinical trials where Cogstate is operating. As
highlighted here, we are seeing increasing demand for central rating – we sold central rating
into 12 clinical trials in FY26, up from 5 the prior year and 3 in FY24.
From a margin perspective, Central Rating remains attractive because it leverages Cogstate's
specialist clinician network and scalable operating model. Much of the delivery cost is
variable and directly aligned with study activity, allowing us to grow this service line while
maintaining service margins consistent with our broader clinical services portfolio.
6
Our channel partner strategy is also gaining material traction. Partner-related contracts
accounted for approximately 40% of new sales in FY26. The Medidata relationship,
alongside collaboration with a growing group of clinical-trial technology partners, is
extending Cogstate’s commercial reach and embedding our capabilities more deeply into
sponsor workflows. These relationships are increasingly becoming a structural feature of
the Company’s go-to-market model, supporting more scalable opportunity flow while
preserving the quality and economics of our offering.
7
7
Partnerships Support Repeatable Growth
• Strategic partnerships are embedding
Cogstate solutions within leading clinical
trial platforms.
• These relationships broaden access to
programs and support a more repeatable
pipeline of opportunities.
• Partnerships and integrations are an
increasing contributor to growth.
Partner related contracts (including eCOA and CRO) accounting for
approx. 40% of value of new sales contracts in FY26.
As the Company grows, the Board is focused on ensuring it has the operating model,
systems and governance needed to scale responsibly.
This is why the continued evolution of Cogstate’s technology platform is so important. The
Company has introduced AI-supported capabilities in central monitoring and rater training,
while retaining human oversight and scientific accountability.
While we will continue to seek to use AI to develop new products for customers, like all
services businesses, we must also think about how AI can transform our operating model
and drive efficiencies. I am very pleased to say that, during FY27, investment will extend
further into workflow orchestration, automation and greater operational transparency
across teams, systems, sponsors, sites and partners. This will be a two-year project that we
expect will deliver small efficiency gains in FY28 and more substantial gains in FY29 and
beyond.
The purpose of these initiatives is practical and disciplined: to protect and enhance quality
as the business expands, improve the customer experience, and enable Cogstate’s
specialists to direct their expertise to where it has the greatest impact. The Board regards
AI as an enabler of better science, stronger quality control and more efficient delivery.
Applied with appropriate governance, it can support a more resilient and scalable operating
model.
8
8
Building an AI-enabled operating platform for modern CNS trials
AI product enhancement, platform evolution
• AI-enabled Rater Training and AI-enabled
Central Monitoring are the first initiatives of a
broader AI-enabled platform for regulated CNS
trial workflows.
• The next phase extends AI and automation
across workflow orchestration and system
integration in trial operations to reduce manual
processes and improve delivery efficiency.
• This strengthens Cogstate’s differentiation as a
trusted technology partner with greater
scalability, stronger margins over time and
deeper pharmaceutical customer engagement.
• Two-year build-out over FY27 & FY28,
predominantly CapEx.
8
The Board’s confidence in Cogstate’s outlook is reflected in the long-term incentive
arrangements that shareholders are asked to consider today, which are anchored on strong
CAGR growth.
These arrangements are designed to align executive reward with the sustained creation of
shareholder value. They do not reward activity alone or place undue emphasis on a single,
short-term outcome. Instead, they are linked to the growth and performance measures
that the Board believes best reflect successful execution of Cogstate’s strategy over time.
9
9
Long Term Incentive
Targets
2025 Grant 2026 Grant
Tranche 1 (50%)
Revenue CAGR
Less than 5% CAGR = Nil
At 14% CAGR = Maximum
Less than 15% CAGR = Nil
At 25% CAGR = Maximum
Straight-line vesting occurs for performance between threshold and maximum
Tranche 2 (50%)
EPS CAGR
Less than 10% CAGR = Nil
At 25% CAGR = Maximum
Less than 15% CAGR = Nil
At 30% CAGR = Maximum
Straight-line vesting occurs for performance between threshold and maximum
EPS: Earnings Per Share
CAGR: Compound Annual Growth Rate
The Board has also been encouraged by the step-up in investor engagement over the past
12 months. We have seen increased interest in Cogstate from the investment community in
both Australia and the United States, alongside an expanded list of institutions joining the
Company’s register. This interest reflects a growing appreciation of Cogstate’s differentiated
position at the intersection of neuroscience, clinical research and technology, and an
external validation of the strength of our growth pathway.
Our Investor Insights Series and inaugural Shareholder Day, held in November 2025, were
important initiatives in strengthening that engagement. The Board remains committed to
clear, accessible and meaningful engagement with shareholders as Cogstate continues to
evolve.
The Board is equally focused on the measured and considered allocation of shareholders’
capital. Our responsibility is to balance three priorities: preserving the financial strength
required to pursue growth opportunities; delivering appropriate and sustainable returns to
shareholders; and investing in the capabilities that will underpin Cogstate’s long-term
competitive advantage.
To this end, the Board is committed to disciplined investment in technology evolution.
Investment in workflow orchestration, automation and AI-enabled delivery is intended to
support higher-quality outcomes, greater efficiency and a more scalable operating
platform. These are deliberate investments in the Company’s ability to grow without
compromising the scientific credibility and service quality on which its reputation depends.
10
10
Capital Management Plans
Capital Expenditure
There is presently a generational opportunity to utilise technology to lift future gross margins.
Therefore, capital expenditure will increase over FY27 and FY28 as we build out an AI powered operating platform
that will enable Cogstate, over the medium term, to improve efficiency and enable expansion of gross margins.
FY26 Annual Dividend
Increased to A$0.04 per share, fully franked, reflecting business confidence and growth prospects.
The payout ratio of approx. 40% of after-tax profits sits comfortably within our stated target of 20% - 50%.
Share Buyback
We have maintained an on-market, share buy-back program. This provides the Company with the flexibility to
reduce shares on issue where the Board considers that to be in shareholders’ best interests.
The technology investment, over FY27 and FY28, is expected to create some operating
efficiency in FY28 but most gains will impact FY29 and beyond.
The Board has introduced an annual dividend policy, reflecting confidence in the Company’s
underlying earnings and cash-generative capacity. The FY26 fully franked dividend of A$0.04
per share is an important expression of that commitment.
We have also maintained an open, on-market, share buy-back program. This provides the
Company with the flexibility to reduce shares on issue where the Board considers that to be
in shareholders’ best interests, while retaining the financial capacity to act on strategic
opportunities and invest in the business.
This balanced approach of returning capital responsibly, maintaining financial flexibility but,
more importantly, investing for the future is central to the Board’s stewardship of your
capital. It reflects our confidence in the opportunity ahead, but also our conviction that
enduring shareholder value is created through careful choices, sustained execution and
financial discipline.
10
Cogstate’s enduring advantage remains the combination of scientific rigour, validated
digital assessments, specialist CNS expertise and a genuine commitment to improving the
quality of clinical evidence. As the business expands, these strengths must remain non-
negotiable.
On behalf of the Board, I thank Brad O’Connor, the leadership team and all Cogstate
employees across the world for their expertise, commitment and focus during the last year.
I also thank my fellow directors for their stewardship and contribution.
Finally, thank you to our shareholders for your continued support and confidence. Cogstate
enters FY27 with a stronger contracted revenue base, greater therapeutic diversification, an
expanding partner ecosystem and a clear pathway to technology-enabled scale.
The Board is confident that Cogstate is well positioned to build on this momentum and to
create enduring value for shareholders, customers and, ultimately, the patients whose lives
may be improved through better brain-health research.
Thank you.
11
11
Thank You
As we grow, we remain committed to scientific rigour and operational
excellence that have brought us this far.
--------------------------------------------------------------------------------------------------
Cogstate Ltd 2026 Annual General Meeting - Managing Director Address to Shareholders
Mr. Brad O’Connor
--------------------------------------------------------------------------------------------------
Firstly, I’d like to thank Martyn and the whole Board for their continued support and also,
formally, welcome Darryl to the Board.
Secondly, I want to acknowledge the ongoing commitment of our broader leadership team
– it is, without doubt, the best team that I have ever had the pleasure of being involved
with. They are hard working and all truly believe that we are building something special
here. It’s a fun place to work; the work we do makes a difference for the lives of sick
people, our team is full of smart, energetic people who want to create something of which
we can all be proud and we find ourselves at a unique moment in time where technology
allows us to completely re-imagine ways of working.
Before we get in to the first quarter results, I wanted to spend a couple of minutes focusing
on the likely sources of growth over the next few years.
There is no doubt that we are seeing an increase in activity, which is supported by the
increase in proposals volumes over the last couple of years. This reflects a general increase
in R&D spend, and therefore trial starts, in Central Nervous System disease areas.
12
12
Sources of Growth
Increased Investment
in CNS Diseases
Indication Expansion Maturation of Current
Portfolio
Service Offering
Expansion
Go-To-Market
Strategy
Increase in trial starts,
generally.
Increased discovery
cadence through AI
Psychiatry and Orexin
programs, incl. recent
M&A as commercial
validation
Expansion of Cogstate
focus areas increases
addressable market
• Psychiatry & Mood
• Mental Health
• Sleep
Expansion of Cogstate
service offering
increases share of
R&D spend
• Central Rating
Continued growth of
opportunities via
channel partners
Ongoing phase 2 trials:
• 45 at 30-Jun-2025
• 78 at 30-Jun-2026
Progress from phase 2
to phase 3 will lead to
increased sales value
1 2 3 4 5
Continuing to think at that macro level, we expect that, over time, a.i. will be used to identify
new drug candidates and therefore, as the cadence of discovery increases, then new-trial
starts should also increase.
More specifically, we see recent M&A activity as a sign of increased R&D spend in areas that
specifically impact Cogstate. For example, Lilly’s acquisition of Centessa and their orexin
program, which closed on 24 June 2026, and also Lilly’s acquisition of Atai Beckley and their
psychedelic program, which closed on 11 September 2026, provide important commercial
validation of increased R&D spend in these areas.
As Martyn has already mentioned, Cogstate’s expansion into new disease areas and the
expansion of service lines offered across all disease areas will continue to increase sales
opportunities for us. In areas where Cogstate is a new entrant to the market, such as mood
and psychiatry, we estimate our market share to be quite low, offering room for growth as
we gain traction within that large market. Additionally, we have seen, over the last year, a
substantial increase in trials utilising central rating and, as this trend continues, we can
expect that revenue from central rating will increase as a percentage of total contracted
revenue.
Obviously, our go-to-market strategy, and specifically our Medidata partnership, is providing
us with more shots on goal and that is a trend that we expect to continue.
Finally, there is the natural growth that comes from our ongoing portfolio of work. When we
win new work, it is generally in early-stage phase 2 trials. If those trials are successful and
the drug moves through to Phase 3, we have a great history of winning that phase 3 work, at
an increased contract value the reflects the increased size and complexity of the phase 3
trial. Through FY26, we saw a significant increase in phase 2 work and that is continuing as
we execute on new sales opportunities in this last September quarter. Over the coming two
years, we can expect many of those phase 2 trials to convert into phase 3 opportunities for
Cogstate.
12
The September quarter sales results demonstrated Cogstate’s ability to win market share in
mood disorders.
Throughout the quarter, we executed $25.1 million of net sales contracts. The sales result
was highly influenced by competitive win of 4 phase 3 trials, while in respect of a separate,
fifth, phase 3 trial we executed the main agreement during the September quarter
following a small start up agreement being executed in late June. The start up agreement,
for a value of less than $100,000, enabled us to start work earlier to ensure that we could
meet study start-up timelines.
These 5 x phase 3 trials, across two customers, contributed approximately 80% of the total
contract sales value executed during the quarter.
In each of these trials, our channel partnership strategy was crucial to winning the
competitive bids. As a general statement, it is difficult to win competitive work at phase 3
– the differentiator in this situation was that our channel partnerships allowed our
customers to work with their preferred data capture technology provider, while our team at
Cogstate was able to successfully demonstrate our expertise and capability in the execution
of complex phase 3 trials.
The absence of larger Alzheimer’s trial wins during the quarter is noted but not considered
a major concern. Our expectation is that Alzheimer’s will be a more prevalent contributor
to sales contracts in calendar year 2027 and that the September quarter results
13
13
Net Sales Contracts Executed
1Q27: $25.13m, up 17% vs 1Q26
• 2% Alzheimer’s.
• 93% Mood, Sleep & Other Neurology.
• 5% Rare Diseases.
• 0% Cancer, Metabolic and Other Diseases.
• Continued contribution through channel partners
• 9 new clinical trials
• 1 x phase 1
• 4 x phase 2
• 4 x phase 3
• Competitive phase 3 wins in bipolar and
depression, demonstrating our ability to take
market share
13
0
5
10
15
20
25
30
1Q25 2Q25 3Q25 4Q25 1Q26 2Q26 3Q26 4Q26 1Q27
US$
Millions
Net Sales Contracts Executed, Per Quarter
demonstrate the strength of a diversified strategy across therapeutic disease areas, broader
service offering and enhanced go-to-market sales strategy.
13
Contracted FY27 revenue increased to $56.8 million at 30 September 2026, from
$48.3 million at 30 June 2026. The $25.1 million in new contracts executed during
1Q27 contributed
Share your feedback
Discover